Endocrine Today Current Issue

The following articles appeared in the print edition of Endocrine Today.

Table of Contents

• The changing landscape of endocrinology: GLP-1s, new diabetes technology and more Michael Monostra; Erik Swain
• Obesity medications can tackle metabolic cardiorenal disease Lance Sloan, MD, MSE, FACE, FASN, FACP, FASPC, FEAA
• 50% of teens have micronutrient deficiencies 10 years after weight-loss surgery Erin T. Welsh, MA
• AI model using voice recognition outperforms endocrinologists for diagnosing acromegaly Michael Monostra
• AI-enabled video of skin on face, hands may detect high blood pressure, diabetes Regina Schaffer
• Cardio-kidney-metabolic syndrome may accelerate CVD risk by up to 28 years Scott Buzby
• Common PCOS treatments do not increase, decrease metabolic syndrome risk Regina Schaffer
• Coronary artery disease screening shows no benefit for individuals with diabetes Moira Mahoney
• Crinecerfont approved to treat congenital adrenal hyperplasia Erik Swain
• Daily oral semaglutide confers weight loss vs. placebo; similar vs. weekly injectables Scott Buzby
• Early weight loss with tirzepatide predictive of larger cardiometabolic benefits later on Scott Buzby
• Endocrinology Drug and Device Update Michael Monostra
• Fractures occurring at any time in adulthood tied to risk for future fractures Erin T. Welsh, MA
• GLP-1 alternative well-tolerated, could lead to similar rate of weight loss Scott Buzby
• GLP-1 medication access limited by care site, payer type, demographics Erin T. Welsh, MA
• GLP-1, SGLT2 prescriptions for type 1 diabetes rising despite no regulatory approval Erik Swain
• GPT-4 responses to anti-obesity medication questions comparable to FDA answers Erin T. Welsh, MA
• Insulin resistance, hyperinsulinemia may predict aortic stenosis in men Erin T. Welsh, MA
• IV GLP-1 does not reduce death, stroke, organ damage after heart surgery Erik Swain
• Lower is better: BPROAD trial backs intensive blood pressure target for patients with diabetes Katie Kalvaitis
• Lower SHBG concentrations tied to reduced fracture risk for men Michael Monostra
• New type 2 diabetes more likely in youth after COVID-19 vs. other respiratory diseases Michael Monostra
• No cognitive impact 10 years after short-term, early menopausal hormone therapy: KEEPS Erin T. Welsh, MA
• Novel GLP-1 analog injection reduced weight for Chinese adults with overweight, obesity Erin T. Welsh, MA
• Novel GLP-1 analog utreglutide confers weight loss, improves leptin resistance Scott Buzby
• Obesity rates decline for first time in a decade Andrew (Drew) Rhoades
• Pioglitazone added to insulin increases ischemic heart disease risk in type 2 diabetes Moira Mahoney
• Policies that restrict fast-food outlets may reduce childhood obesity in deprived areas Moira Mahoney
• Q&A: What men with diabetes should know about reducing risk for erectile dysfunction Susan Weiner, MS, RDN, CDN, CDCES, FADCES; Brenda Jagatic, BScN, RN, CDCES
• Retatrutide linked to improved health-related quality of life plus weight loss Scott Buzby
• Severe carbohydrate restriction not necessary for ketosis, weight loss in low-energy diets Moira Mahoney
• SGLT2s, GLP-1s may improve mortality, CV event risk after stroke Scott Buzby
• VIDEO: GLP-1s ‘not the only tool in our armamentarium’ for obesity treatment Katherine H. Saunders, MD, DABOM
• Zepbound bests Wegovy in head-to-head weight-loss trial Erik Swain